ID   DAPK1_HUMAN             Reviewed;        1430 AA.
AC   P53355; B7ZLD2; B7ZLE7; Q14CQ7; Q1W5W0; Q68CP8; Q6ZRZ3; Q9BTL8;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 6.
DT   12-OCT-2022, entry version 226.
DE   RecName: Full=Death-associated protein kinase 1;
DE            Short=DAP kinase 1;
DE            EC=2.7.11.1;
GN   Name=DAPK1; Synonyms=DAPK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INDUCTION, MUTAGENESIS OF
RP   LYS-42, AND VARIANT ASN-1346.
RX   PubMed=7828849; DOI=10.1101/gad.9.1.15;
RA   Deiss L.P., Feinstein E., Berissi H., Cohen O., Kimchi A.;
RT   "Identification of a novel serine/threonine kinase and a novel 15-kD
RT   protein as potential mediators of the gamma interferon-induced cell
RT   death.";
RL   Genes Dev. 9:15-30(1995).
RN   [2]
RP   SEQUENCE REVISION TO 164-171.
RA   Feinstein E.;
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ASN-1346.
RC   TISSUE=Amygdala;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-591; MET-622; ASN-1346
RP   AND VAL-1405.
RG   NIEHS SNPs program;
RL   Submitted (MAR-2006) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASN-1346.
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4).
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-363.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=10629061; DOI=10.1128/mcb.20.3.1044-1054.2000;
RA   Inbal B., Shani G., Cohen O., Kissil J.L., Kimchi A.;
RT   "Death-associated protein kinase-related protein 1, a novel
RT   serine/threonine kinase involved in apoptosis.";
RL   Mol. Cell. Biol. 20:1044-1054(2000).
RN   [11]
RP   FUNCTION, ACTIVITY REGULATION, MUTAGENESIS OF LYS-42; SER-308 AND SER-313,
RP   AND PHOSPHORYLATION AT SER-308.
RX   PubMed=11579085; DOI=10.1074/jbc.m105133200;
RA   Shohat G., Spivak-Kroizman T., Cohen O., Bialik S., Shani G., Berissi H.,
RA   Eisenstein M., Kimchi A.;
RT   "The pro-apoptotic function of death-associated protein kinase is
RT   controlled by a unique inhibitory autophosphorylation-based mechanism.";
RL   J. Biol. Chem. 276:47460-47467(2001).
RN   [12]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11980920; DOI=10.1083/jcb.200109094;
RA   Inbal B., Bialik S., Sabanay I., Shani G., Kimchi A.;
RT   "DAP kinase and DRP-1 mediate membrane blebbing and the formation of
RT   autophagic vesicles during programmed cell death.";
RL   J. Cell Biol. 157:455-468(2002).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF STX1A, AND INTERACTION WITH STX1A.
RX   PubMed=12730201; DOI=10.1074/jbc.m300492200;
RA   Tian J.H., Das S., Sheng Z.H.;
RT   "Ca2+-dependent phosphorylation of syntaxin-1A by the death-associated
RT   protein (DAP) kinase regulates its interaction with Munc18.";
RL   J. Biol. Chem. 278:26265-26274(2003).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF DAPK3, AND INTERACTION WITH DAPK3.
RX   PubMed=15367680; DOI=10.1128/mcb.24.19.8611-8626.2004;
RA   Shani G., Marash L., Gozuacik D., Bialik S., Teitelbaum L., Shohat G.,
RA   Kimchi A.;
RT   "Death-associated protein kinase phosphorylates ZIP kinase, forming a
RT   unique kinase hierarchy to activate its cell death functions.";
RL   Mol. Cell. Biol. 24:8611-8626(2004).
RN   [15]
RP   INTERACTION WITH PDCD6.
RX   PubMed=16132846; DOI=10.1007/s10529-005-7869-x;
RA   Lee J.H., Rho S.B., Chun T.;
RT   "Programmed cell death 6 (PDCD6) protein interacts with death-associated
RT   protein kinase 1 (DAPk1): additive effect on apoptosis via caspase-3
RT   dependent pathway.";
RL   Biotechnol. Lett. 27:1011-1015(2005).
RN   [16]
RP   PHOSPHORYLATION AT SER-289.
RX   PubMed=16213824; DOI=10.1016/j.cub.2005.08.050;
RA   Anjum R., Roux P.P., Ballif B.A., Gygi S.P., Blenis J.;
RT   "The tumor suppressor DAP kinase is a target of RSK-mediated survival
RT   signaling.";
RL   Curr. Biol. 15:1762-1767(2005).
RN   [17]
RP   PHOSPHORYLATION AT SER-734, AND INTERACTION WITH MAPK1 AND MAPK3.
RX   PubMed=15616583; DOI=10.1038/sj.emboj.7600510;
RA   Chen C.H., Wang W.J., Kuo J.C., Tsai H.C., Lin J.R., Chang Z.F., Chen R.H.;
RT   "Bidirectional signals transduced by DAPK-ERK interaction promote the
RT   apoptotic effect of DAPK.";
RL   EMBO J. 24:294-304(2005).
RN   [18]
RP   PHOSPHORYLATION AT SER-308, ACTIVITY REGULATION, AND INTERACTION WITH
RP   UNC5B.
RX   PubMed=15729359; DOI=10.1038/sj.emboj.7600584;
RA   Llambi F., Lourenco F.C., Gozuacik D., Guix C., Pays L., Del Rio G.,
RA   Kimchi A., Mehlen P.;
RT   "The dependence receptor UNC5H2 mediates apoptosis through DAP-kinase.";
RL   EMBO J. 24:1192-1201(2005).
RN   [19]
RP   REVIEW ON FUNCTION.
RX   PubMed=16756490; DOI=10.1146/annurev.biochem.75.103004.142615;
RA   Bialik S., Kimchi A.;
RT   "The death-associated protein kinases: structure, function, and beyond.";
RL   Annu. Rev. Biochem. 75:189-210(2006).
RN   [20]
RP   ALTERNATIVE SPLICING (ISOFORM 3), PHOSPHORYLATION AT SER-308,
RP   DEPHOSPHORYLATION, AND ACTIVITY REGULATION.
RX   PubMed=17056602; DOI=10.1074/jbc.m605097200;
RA   Jin Y., Blue E.K., Gallagher P.J.;
RT   "Control of death-associated protein kinase (DAPK) activity by
RT   phosphorylation and proteasomal degradation.";
RL   J. Biol. Chem. 281:39033-39040(2006).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF PRKD1, AND INTERACTION WITH PRKD1.
RX   PubMed=17703233; DOI=10.1038/sj.cdd.4402212;
RA   Eisenberg-Lerner A., Kimchi A.;
RT   "DAP kinase regulates JNK signaling by binding and activating protein
RT   kinase D under oxidative stress.";
RL   Cell Death Differ. 14:1908-1915(2007).
RN   [22]
RP   FUNCTION IN PHOSPHORYLATION OF TPM1.
RX   PubMed=17895359; DOI=10.1242/jcs.003251;
RA   Houle F., Poirier A., Dumaresq J., Huot J.;
RT   "DAP kinase mediates the phosphorylation of tropomyosin-1 downstream of the
RT   ERK pathway, which regulates the formation of stress fibers in response to
RT   oxidative stress.";
RL   J. Cell Sci. 120:3666-3677(2007).
RN   [23]
RP   ALTERNATIVE SPLICING (ISOFORM 2), PROTEOLYTIC PROCESSING, FUNCTION,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=18422656; DOI=10.1111/j.1742-4658.2008.06404.x;
RA   Lin Y., Stevens C., Hrstka R., Harrison B., Fourtouna A., Pathuri S.,
RA   Vojtesek B., Hupp T.;
RT   "An alternative transcript from the death-associated protein kinase 1 locus
RT   encoding a small protein selectively mediates membrane blebbing.";
RL   FEBS J. 275:2574-2584(2008).
RN   [24]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MAP1B.
RX   PubMed=18195017; DOI=10.1074/jbc.m706040200;
RA   Harrison B., Kraus M., Burch L., Stevens C., Craig A., Gordon-Weeks P.,
RA   Hupp T.R.;
RT   "DAPK-1 binding to a linear peptide motif in MAP1B stimulates autophagy and
RT   membrane blebbing.";
RL   J. Biol. Chem. 283:9999-10014(2008).
RN   [25]
RP   FUNCTION.
RX   PubMed=18995835; DOI=10.1016/j.molcel.2008.09.019;
RA   Mukhopadhyay R., Ray P.S., Arif A., Brady A.K., Kinter M., Fox P.L.;
RT   "DAPK-ZIPK-L13a axis constitutes a negative-feedback module regulating
RT   inflammatory gene expression.";
RL   Mol. Cell 32:371-382(2008).
RN   [26]
RP   FUNCTION IN PHOSPHORYLATION OF BECN1, AND INTERACTION WITH BECN1.
RX   PubMed=19180116; DOI=10.1038/embor.2008.246;
RA   Zalckvar E., Berissi H., Mizrachy L., Idelchuk Y., Koren I., Eisenstein M.,
RA   Sabanay H., Pinkas-Kramarski R., Kimchi A.;
RT   "DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes
RT   dissociation of beclin 1 from Bcl-XL and induction of autophagy.";
RL   EMBO Rep. 10:285-292(2009).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF TSC2 AND RPS6, AND INTERACTION WITH TSC2.
RX   PubMed=18974095; DOI=10.1074/jbc.m805165200;
RA   Stevens C., Lin Y., Harrison B., Burch L., Ridgway R.A., Sansom O.,
RA   Hupp T.;
RT   "Peptide combinatorial libraries identify TSC2 as a death-associated
RT   protein kinase (DAPK) death domain-binding protein and reveal a stimulatory
RT   role for DAPK in mTORC1 signaling.";
RL   J. Biol. Chem. 284:334-344(2009).
RN   [28]
RP   UBIQUITINATION, AND INTERACTION WITH KLHL20.
RX   PubMed=20389280; DOI=10.1038/emboj.2010.62;
RA   Lee Y.R., Yuan W.C., Ho H.C., Chen C.H., Shih H.M., Chen R.H.;
RT   "The Cullin 3 substrate adaptor KLHL20 mediates DAPK ubiquitination to
RT   control interferon responses.";
RL   EMBO J. 29:1748-1761(2010).
RN   [29]
RP   REVIEW ON FUNCTION.
RX   PubMed=19878313; DOI=10.1111/j.1742-4658.2009.07411.x;
RA   Lin Y., Hupp T.R., Stevens C.;
RT   "Death-associated protein kinase (DAPK) and signal transduction: additional
RT   roles beyond cell death.";
RL   FEBS J. 277:48-57(2010).
RN   [30]
RP   FUNCTION IN PHOSPHORYLATION OF PIN1, AND INTERACTION WITH PIN1.
RX   PubMed=21497122; DOI=10.1016/j.molcel.2011.03.005;
RA   Lee T.H., Chen C.H., Suizu F., Huang P., Schiene-Fischer C., Daum S.,
RA   Zhang Y.J., Goate A., Chen R.H., Zhou X.Z., Lu K.P.;
RT   "Death-associated protein kinase 1 phosphorylates Pin1 and inhibits its
RT   prolyl isomerase activity and cellular function.";
RL   Mol. Cell 42:147-159(2011).
RN   [31]
RP   FUNCTION.
RX   PubMed=21408167; DOI=10.1371/journal.pone.0017344;
RA   Shoval Y., Berissi H., Kimchi A., Pietrokovski S.;
RT   "New modularity of DAP-kinases: alternative splicing of the DRP-1 gene
RT   produces a ZIPk-like isoform.";
RL   PLoS ONE 6:E17344-E17344(2011).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-333, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-319, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-333, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   INTERACTION WITH UNC5C.
RX   PubMed=27068745; DOI=10.1074/jbc.m115.698092;
RA   Hashimoto Y., Toyama Y., Kusakari S., Nawa M., Matsuoka M.;
RT   "An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor
RT   Uncoordinated-5C-induced Signaling That Merges with Amyloid beta Precursor
RT   Protein Signaling.";
RL   J. Biol. Chem. 291:12282-12293(2016).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 2-285 IN COMPLEX WITH ATP ANALOG
RP   AND DIVALENT METAL CATION.
RX   PubMed=11573098; DOI=10.1038/nsb1001-899;
RA   Tereshko V., Teplova M., Brunzelle J., Watterson D.M., Egli M.;
RT   "Crystal structures of the catalytic domain of human protein kinase
RT   associated with apoptosis and tumor suppression.";
RL   Nat. Struct. Biol. 8:899-907(2001).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 2-285 IN COMPLEX WITH SYNTHETIC
RP   INHIBITOR.
RX   PubMed=14505650; DOI=10.1016/s0960-894x(03)00733-9;
RA   Velentza A.V., Wainwright M.S., Zasadzki M., Mirzoeva S., Schumacher A.M.,
RA   Haiech J., Focia P.J., Egli M., Watterson D.M.;
RT   "An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase
RT   attenuates hypoxia-ischemia induced acute brain injury.";
RL   Bioorg. Med. Chem. Lett. 13:3465-3470(2003).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1-278 IN COMPLEX WITH INHIBITORS.
RA   Ueda Y., Ogata H., Yamakawa A., Higuchi Y.;
RT   "Complex structure of kinase domain of DAP kinase with staurosporine.";
RL   Submitted (APR-2006) to the PDB data bank.
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 302-320 IN COMPLEX WITH
RP   CALMODULIN.
RA   Kursula P., Vahokoski J., Wilmanns M.;
RT   "Recognition of human death-associated protein kinases by calmodulin.";
RL   Submitted (JUL-2006) to the PDB data bank.
RN   [40]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-416; SER-461; ALA-519; TYR-540;
RP   THR-941; TRP-977; ASN-978; CYS-993; GLU-994; GLN-1005; TYR-1007; PRO-1008;
RP   CYS-1010; ALA-1018; ILE-1272; ASN-1346 AND VAL-1405.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Calcium/calmodulin-dependent serine/threonine kinase involved
CC       in multiple cellular signaling pathways that trigger cell survival,
CC       apoptosis, and autophagy. Regulates both type I apoptotic and type II
CC       autophagic cell deaths signal, depending on the cellular setting. The
CC       former is caspase-dependent, while the latter is caspase-independent
CC       and is characterized by the accumulation of autophagic vesicles.
CC       Phosphorylates PIN1 resulting in inhibition of its catalytic activity,
CC       nuclear localization, and cellular function. Phosphorylates TPM1,
CC       enhancing stress fiber formation in endothelial cells. Phosphorylates
CC       STX1A and significantly decreases its binding to STXBP1. Phosphorylates
CC       PRKD1 and regulates JNK signaling by binding and activating PRKD1 under
CC       oxidative stress. Phosphorylates BECN1, reducing its interaction with
CC       BCL2 and BCL2L1 and promoting the induction of autophagy.
CC       Phosphorylates TSC2, disrupting the TSC1-TSC2 complex and stimulating
CC       mTORC1 activity in a growth factor-dependent pathway. Phosphorylates
CC       RPS6, MYL9 and DAPK3. Acts as a signaling amplifier of NMDA receptors
CC       at extrasynaptic sites for mediating brain damage in stroke. Cerebral
CC       ischemia recruits DAPK1 into the NMDA receptor complex and it
CC       phosphorylates GRINB at Ser-1303 inducing injurious Ca(2+) influx
CC       through NMDA receptor channels, resulting in an irreversible neuronal
CC       death. Required together with DAPK3 for phosphorylation of RPL13A upon
CC       interferon-gamma activation which is causing RPL13A involvement in
CC       transcript-selective translation inhibition.
CC   -!- FUNCTION: Isoform 2 cannot induce apoptosis but can induce membrane
CC       blebbing.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Activated by Ca(2+)/calmodulin. Regulated by a
CC       locking mechanism, involving autophosphorylation at Ser-308 and
CC       calmodulin binding. In the inactive state, Ser-308 is phosphorylated.
CC       Activation involves its dephosphorylation and a release-of-
CC       autoinhibition mechanism where binding of calmodulin induces a
CC       conformational change that relieves the steric block of the active site
CC       by the autoinhibitory domain. Activity is modulated by UNC5B and NTN1.
CC       UNC5B activates it by inhibiting the phosphorylation at Ser-308,
CC       whereas NTN1 inhibits UNC5B-mediated activation of DAPK1. Endoplasmic-
CC       stress activates by causing Ser-308 dephosphorylation.
CC       {ECO:0000269|PubMed:11579085, ECO:0000269|PubMed:15729359,
CC       ECO:0000269|PubMed:17056602}.
CC   -!- SUBUNIT: Interacts with KLHL20 (PubMed:20389280). Interacts (via death
CC       domain) with MAPK1 and MAPK3 (PubMed:15616583). Interacts with MAP1B
CC       (via N-terminus) (PubMed:18195017). Interacts with PRKD1 in an
CC       oxidative stress-regulated manner (PubMed:17703233). Interacts with
CC       PIN1, PDCD6, BECN1, TSC2 and STX1A (PubMed:12730201, PubMed:16132846,
CC       PubMed:18974095, PubMed:19180116, PubMed:21497122). Interacts (via
CC       kinase domain) with DAPK3 (via kinase domain) (PubMed:15367680).
CC       Interacts with GRINB (By similarity). Interacts (via death domain) with
CC       UNC5B (via death domain) (PubMed:15729359). Interacts with UNC5C (via
CC       death domain) (PubMed:27068745). {ECO:0000250|UniProtKB:Q80YE7,
CC       ECO:0000269|PubMed:12730201, ECO:0000269|PubMed:15367680,
CC       ECO:0000269|PubMed:15616583, ECO:0000269|PubMed:15729359,
CC       ECO:0000269|PubMed:16132846, ECO:0000269|PubMed:17703233,
CC       ECO:0000269|PubMed:18195017, ECO:0000269|PubMed:18974095,
CC       ECO:0000269|PubMed:19180116, ECO:0000269|PubMed:20389280,
CC       ECO:0000269|PubMed:21497122, ECO:0000269|PubMed:27068745}.
CC   -!- INTERACTION:
CC       P53355; O95816: BAG2; NbExp=3; IntAct=EBI-358616, EBI-355275;
CC       P53355; Q14457: BECN1; NbExp=4; IntAct=EBI-358616, EBI-949378;
CC       P53355; P62158: CALM3; NbExp=6; IntAct=EBI-358616, EBI-397435;
CC       P53355; P53355: DAPK1; NbExp=6; IntAct=EBI-358616, EBI-358616;
CC       P53355; Q9Y2M5: KLHL20; NbExp=11; IntAct=EBI-358616, EBI-714379;
CC       P53355; Q9UHB6: LIMA1; NbExp=2; IntAct=EBI-358616, EBI-351479;
CC       P53355; Q38SD2: LRRK1; NbExp=2; IntAct=EBI-358616, EBI-1050422;
CC       P53355; Q5S007: LRRK2; NbExp=2; IntAct=EBI-358616, EBI-5323863;
CC       P53355; P27361: MAPK3; NbExp=5; IntAct=EBI-358616, EBI-73995;
CC       P53355; O75340: PDCD6; NbExp=3; IntAct=EBI-358616, EBI-352915;
CC       P53355; P14618: PKM; NbExp=3; IntAct=EBI-358616, EBI-353408;
CC       P53355; P14618-1: PKM; NbExp=2; IntAct=EBI-358616, EBI-4304679;
CC       P53355; P63151: PPP2R2A; NbExp=3; IntAct=EBI-358616, EBI-1048931;
CC       P53355; Q9UNE7: STUB1; NbExp=2; IntAct=EBI-358616, EBI-357085;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cytoplasm. Cytoplasm, cytoskeleton.
CC       Note=Colocalizes with MAP1B in the microtubules and cortical actin
CC       fibers.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm. Cytoplasm, cytoskeleton.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Alpha;
CC         IsoId=P53355-1; Sequence=Displayed;
CC       Name=2; Synonyms=s-DAPK-1;
CC         IsoId=P53355-2; Sequence=VSP_042053, VSP_042054, VSP_042055;
CC       Name=3; Synonyms=Beta;
CC         IsoId=P53355-3; Sequence=VSP_042056;
CC       Name=4;
CC         IsoId=P53355-4; Sequence=VSP_054478;
CC   -!- TISSUE SPECIFICITY: Isoform 2 is expressed in normal intestinal tissue
CC       as well as in colorectal carcinomas. {ECO:0000269|PubMed:18422656}.
CC   -!- INDUCTION: Up-regulated following treatment with IFNG/IFN-gamma.
CC       {ECO:0000269|PubMed:7828849}.
CC   -!- DOMAIN: The autoinhibitory domain sterically blocks the substrate
CC       peptide-binding site by making both hydrophobic and electrostatic
CC       contacts with the kinase core.
CC   -!- PTM: Ubiquitinated by the BCR(KLHL20) E3 ubiquitin ligase complex,
CC       leading to its degradation by the proteasome.
CC       {ECO:0000269|PubMed:20389280}.
CC   -!- PTM: Removal of the C-terminal tail of isoform 2 (corresponding to
CC       amino acids 296-337 of isoform 2) by proteolytic cleavage stimulates
CC       maximally its membrane-blebbing function.
CC       {ECO:0000269|PubMed:18422656}.
CC   -!- PTM: In response to mitogenic stimulation (PMA or EGF), phosphorylated
CC       at Ser-289; phosphorylation suppresses DAPK1 pro-apoptotic function.
CC       Autophosphorylation at Ser-308 inhibits its catalytic activity.
CC       Phosphorylation at Ser-734 by MAPK1 increases its catalytic activity
CC       and promotes cytoplasmic retention of MAPK1. Endoplasmic-stress can
CC       cause dephosphorylation at Ser-308. {ECO:0000269|PubMed:11579085,
CC       ECO:0000269|PubMed:15616583, ECO:0000269|PubMed:15729359,
CC       ECO:0000269|PubMed:16213824, ECO:0000269|PubMed:17056602}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. DAP kinase subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAP35581.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the C-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA53712.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/dapk1/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/DAPK1ID417ch9q21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X76104; CAA53712.1; ALT_FRAME; mRNA.
DR   EMBL; AK127855; BAC87163.1; -; mRNA.
DR   EMBL; CR749834; CAH18690.1; -; mRNA.
DR   EMBL; DQ436495; ABD96827.1; -; Genomic_DNA.
DR   EMBL; AL160279; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL161787; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL591852; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471089; EAW62727.1; -; Genomic_DNA.
DR   EMBL; BC113660; AAI13661.1; -; mRNA.
DR   EMBL; BC143733; AAI43734.1; -; mRNA.
DR   EMBL; BC143759; AAI43760.1; -; mRNA.
DR   EMBL; BT006935; AAP35581.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS43842.1; -. [P53355-1]
DR   PIR; I37275; I37275.
DR   RefSeq; NP_001275658.1; NM_001288729.1. [P53355-1]
DR   RefSeq; NP_001275659.1; NM_001288730.1. [P53355-1]
DR   RefSeq; NP_001275660.1; NM_001288731.1. [P53355-1]
DR   RefSeq; NP_004929.2; NM_004938.3. [P53355-1]
DR   PDB; 1IG1; X-ray; 1.80 A; A=2-285.
DR   PDB; 1JKK; X-ray; 2.40 A; A=2-285.
DR   PDB; 1JKL; X-ray; 1.62 A; A=2-285.
DR   PDB; 1JKS; X-ray; 1.50 A; A=2-285.
DR   PDB; 1JKT; X-ray; 3.50 A; A/B=2-285.
DR   PDB; 1P4F; X-ray; 1.90 A; A=2-285.
DR   PDB; 1WVW; X-ray; 2.40 A; A=1-278.
DR   PDB; 1WVX; X-ray; 2.60 A; A=1-278.
DR   PDB; 1WVY; X-ray; 2.80 A; A=1-278.
DR   PDB; 1YR5; X-ray; 1.70 A; B=302-320.
DR   PDB; 2W4J; X-ray; 1.30 A; A=1-277.
DR   PDB; 2W4K; X-ray; 1.90 A; A=1-302.
DR   PDB; 2X0G; X-ray; 2.20 A; A=1-334.
DR   PDB; 2XUU; X-ray; 1.80 A; A=1-334.
DR   PDB; 2XZS; X-ray; 2.00 A; A/B=2-312.
DR   PDB; 2Y0A; X-ray; 2.60 A; A=2-304.
DR   PDB; 2Y4P; X-ray; 2.65 A; A/B/C/D=1-285.
DR   PDB; 2Y4V; X-ray; 1.80 A; B=302-320.
DR   PDB; 2YAK; X-ray; 2.20 A; A=1-285.
DR   PDB; 3DFC; X-ray; 1.90 A; B=1-285.
DR   PDB; 3DGK; X-ray; 1.70 A; A=1-285.
DR   PDB; 3EH9; X-ray; 1.70 A; A=2-285.
DR   PDB; 3EHA; X-ray; 1.60 A; A=2-285.
DR   PDB; 3F5G; X-ray; 1.85 A; A=2-285.
DR   PDB; 3F5U; X-ray; 2.00 A; A=1-285.
DR   PDB; 3GU4; X-ray; 1.35 A; A=1-285.
DR   PDB; 3GU5; X-ray; 1.65 A; A=1-285.
DR   PDB; 3GU6; X-ray; 1.49 A; A=1-285.
DR   PDB; 3GU7; X-ray; 1.90 A; A=1-285.
DR   PDB; 3GU8; X-ray; 1.60 A; A=1-285.
DR   PDB; 3GUB; X-ray; 1.71 A; A=1-285.
DR   PDB; 3ZXT; X-ray; 2.65 A; A/B/C/D=1-285.
DR   PDB; 4B4L; X-ray; 1.75 A; A=1-334.
DR   PDB; 4PF4; X-ray; 1.13 A; A=1-277.
DR   PDB; 4TL0; X-ray; 2.70 A; A=1-334.
DR   PDB; 4TXC; X-ray; 1.95 A; A=1-285.
DR   PDB; 4UV0; X-ray; 2.49 A; A=1-321.
DR   PDB; 4YO4; X-ray; 1.60 A; A=2-285.
DR   PDB; 4YPD; X-ray; 1.40 A; A=2-285.
DR   PDB; 5AUT; X-ray; 1.70 A; A=1-285.
DR   PDB; 5AUU; X-ray; 1.70 A; A=1-285.
DR   PDB; 5AUV; X-ray; 1.50 A; A=1-285.
DR   PDB; 5AUW; X-ray; 1.50 A; A=1-285.
DR   PDB; 5AUX; X-ray; 1.50 A; A=1-285.
DR   PDB; 5AUY; X-ray; 2.00 A; A=1-285.
DR   PDB; 5AUZ; X-ray; 1.60 A; A=1-285.
DR   PDB; 5AV0; X-ray; 1.85 A; A=1-285.
DR   PDB; 5AV1; X-ray; 1.50 A; A=1-285.
DR   PDB; 5AV2; X-ray; 1.50 A; A=1-285.
DR   PDB; 5AV3; X-ray; 1.90 A; A=1-285.
DR   PDB; 5AV4; X-ray; 1.40 A; A=1-285.
DR   PDB; 6AAR; X-ray; 1.95 A; A=1-285.
DR   PDB; 6FHA; X-ray; 2.30 A; A=2-334.
DR   PDB; 6FHB; X-ray; 1.75 A; A=2-334.
DR   PDB; 6GY5; X-ray; 1.09 A; U=1334-1344.
DR   PDB; 6IN4; X-ray; 1.80 A; A=1-285.
DR   PDB; 6QMO; X-ray; 1.87 A; A=2-310.
DR   PDB; 6QN4; X-ray; 2.50 A; A=2-310.
DR   PDB; 7CCU; X-ray; 1.65 A; A=1-285.
DR   PDB; 7CCV; X-ray; 1.75 A; A=1-285.
DR   PDB; 7CCW; X-ray; 1.40 A; A=1-285.
DR   PDBsum; 1IG1; -.
DR   PDBsum; 1JKK; -.
DR   PDBsum; 1JKL; -.
DR   PDBsum; 1JKS; -.
DR   PDBsum; 1JKT; -.
DR   PDBsum; 1P4F; -.
DR   PDBsum; 1WVW; -.
DR   PDBsum; 1WVX; -.
DR   PDBsum; 1WVY; -.
DR   PDBsum; 1YR5; -.
DR   PDBsum; 2W4J; -.
DR   PDBsum; 2W4K; -.
DR   PDBsum; 2X0G; -.
DR   PDBsum; 2XUU; -.
DR   PDBsum; 2XZS; -.
DR   PDBsum; 2Y0A; -.
DR   PDBsum; 2Y4P; -.
DR   PDBsum; 2Y4V; -.
DR   PDBsum; 2YAK; -.
DR   PDBsum; 3DFC; -.
DR   PDBsum; 3DGK; -.
DR   PDBsum; 3EH9; -.
DR   PDBsum; 3EHA; -.
DR   PDBsum; 3F5G; -.
DR   PDBsum; 3F5U; -.
DR   PDBsum; 3GU4; -.
DR   PDBsum; 3GU5; -.
DR   PDBsum; 3GU6; -.
DR   PDBsum; 3GU7; -.
DR   PDBsum; 3GU8; -.
DR   PDBsum; 3GUB; -.
DR   PDBsum; 3ZXT; -.
DR   PDBsum; 4B4L; -.
DR   PDBsum; 4PF4; -.
DR   PDBsum; 4TL0; -.
DR   PDBsum; 4TXC; -.
DR   PDBsum; 4UV0; -.
DR   PDBsum; 4YO4; -.
DR   PDBsum; 4YPD; -.
DR   PDBsum; 5AUT; -.
DR   PDBsum; 5AUU; -.
DR   PDBsum; 5AUV; -.
DR   PDBsum; 5AUW; -.
DR   PDBsum; 5AUX; -.
DR   PDBsum; 5AUY; -.
DR   PDBsum; 5AUZ; -.
DR   PDBsum; 5AV0; -.
DR   PDBsum; 5AV1; -.
DR   PDBsum; 5AV2; -.
DR   PDBsum; 5AV3; -.
DR   PDBsum; 5AV4; -.
DR   PDBsum; 6AAR; -.
DR   PDBsum; 6FHA; -.
DR   PDBsum; 6FHB; -.
DR   PDBsum; 6GY5; -.
DR   PDBsum; 6IN4; -.
DR   PDBsum; 6QMO; -.
DR   PDBsum; 6QN4; -.
DR   PDBsum; 7CCU; -.
DR   PDBsum; 7CCV; -.
DR   PDBsum; 7CCW; -.
DR   AlphaFoldDB; P53355; -.
DR   SMR; P53355; -.
DR   BioGRID; 107982; 149.
DR   ComplexPortal; CPX-102; DAPK1 - calmodulin complex.
DR   IntAct; P53355; 171.
DR   MINT; P53355; -.
DR   STRING; 9606.ENSP00000386135; -.
DR   BindingDB; P53355; -.
DR   ChEMBL; CHEMBL2558; -.
DR   DrugBank; DB04069; 5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine.
DR   DrugBank; DB07444; 6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   DrugCentral; P53355; -.
DR   GuidetoPHARMACOLOGY; 2002; -.
DR   iPTMnet; P53355; -.
DR   PhosphoSitePlus; P53355; -.
DR   BioMuta; DAPK1; -.
DR   DMDM; 317373595; -.
DR   EPD; P53355; -.
DR   jPOST; P53355; -.
DR   MassIVE; P53355; -.
DR   MaxQB; P53355; -.
DR   PaxDb; P53355; -.
DR   PeptideAtlas; P53355; -.
DR   PRIDE; P53355; -.
DR   ProteomicsDB; 56570; -. [P53355-1]
DR   ProteomicsDB; 56571; -. [P53355-2]
DR   ProteomicsDB; 56572; -. [P53355-3]
DR   ProteomicsDB; 7221; -.
DR   Antibodypedia; 6771; 415 antibodies from 36 providers.
DR   DNASU; 1612; -.
DR   Ensembl; ENST00000358077.9; ENSP00000350785.5; ENSG00000196730.13. [P53355-1]
DR   Ensembl; ENST00000408954.8; ENSP00000386135.3; ENSG00000196730.13. [P53355-1]
DR   Ensembl; ENST00000469640.6; ENSP00000418885.3; ENSG00000196730.13. [P53355-4]
DR   Ensembl; ENST00000472284.5; ENSP00000417076.1; ENSG00000196730.13. [P53355-1]
DR   Ensembl; ENST00000491893.5; ENSP00000419026.1; ENSG00000196730.13. [P53355-4]
DR   Ensembl; ENST00000622514.4; ENSP00000484267.1; ENSG00000196730.13. [P53355-1]
DR   GeneID; 1612; -.
DR   KEGG; hsa:1612; -.
DR   MANE-Select; ENST00000408954.8; ENSP00000386135.3; NM_004938.4; NP_004929.2.
DR   UCSC; uc004apc.5; human. [P53355-1]
DR   CTD; 1612; -.
DR   DisGeNET; 1612; -.
DR   GeneCards; DAPK1; -.
DR   HGNC; HGNC:2674; DAPK1.
DR   HPA; ENSG00000196730; Low tissue specificity.
DR   MIM; 600831; gene.
DR   neXtProt; NX_P53355; -.
DR   OpenTargets; ENSG00000196730; -.
DR   PharmGKB; PA27142; -.
DR   VEuPathDB; HostDB:ENSG00000196730; -.
DR   eggNOG; KOG0032; Eukaryota.
DR   GeneTree; ENSGT00940000153424; -.
DR   HOGENOM; CLU_002849_2_0_1; -.
DR   InParanoid; P53355; -.
DR   OrthoDB; 67579at2759; -.
DR   PhylomeDB; P53355; -.
DR   TreeFam; TF314166; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; P53355; -.
DR   Reactome; R-HSA-418889; Caspase activation via Dependence Receptors in the absence of ligand.
DR   SignaLink; P53355; -.
DR   SIGNOR; P53355; -.
DR   BioGRID-ORCS; 1612; 14 hits in 1114 CRISPR screens.
DR   ChiTaRS; DAPK1; human.
DR   EvolutionaryTrace; P53355; -.
DR   GeneWiki; DAPK1; -.
DR   GenomeRNAi; 1612; -.
DR   Pharos; P53355; Tchem.
DR   PRO; PR:P53355; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; P53355; protein.
DR   Bgee; ENSG00000196730; Expressed in germinal epithelium of ovary and 192 other tissues.
DR   ExpressionAtlas; P53355; baseline and differential.
DR   Genevisible; P53355; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:1990722; C:DAPK1-calmodulin complex; IPI:ComplexPortal.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB.
DR   GO; GO:0004683; F:calmodulin-dependent protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0017075; F:syntaxin-1 binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IMP:UniProtKB.
DR   GO; GO:0097190; P:apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0071447; P:cellular response to hydroperoxide; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IDA:UniProtKB.
DR   GO; GO:0002357; P:defense response to tumor cell; IMP:ARUK-UCL.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:ComplexPortal.
DR   GO; GO:1904094; P:positive regulation of autophagic cell death; IMP:ComplexPortal.
DR   GO; GO:0010508; P:positive regulation of autophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0010506; P:regulation of autophagy; TAS:UniProtKB.
DR   GO; GO:2000310; P:regulation of NMDA receptor activity; ISS:UniProtKB.
DR   GO; GO:0002834; P:regulation of response to tumor cell; IDA:ComplexPortal.
DR   Gene3D; 1.10.533.10; -; 1.
DR   Gene3D; 1.25.40.20; -; 3.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR020676; DAPK1.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR020859; ROC_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24342:SF17; PTHR24342:SF17; 1.
DR   Pfam; PF00023; Ank; 1.
DR   Pfam; PF12796; Ank_2; 2.
DR   Pfam; PF13637; Ank_4; 1.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01415; ANKYRIN.
DR   SMART; SM00248; ANK; 9.
DR   SMART; SM00005; DEATH; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 7.
DR   PROSITE; PS50017; DEATH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS51424; ROC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ANK repeat; Apoptosis; ATP-binding;
KW   Calmodulin-binding; Cytoplasm; Cytoskeleton; GTP-binding; Kinase;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Translation regulation;
KW   Ubl conjugation.
FT   CHAIN           1..1430
FT                   /note="Death-associated protein kinase 1"
FT                   /id="PRO_0000085910"
FT   DOMAIN          13..275
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REPEAT          378..407
FT                   /note="ANK 1"
FT   REPEAT          411..440
FT                   /note="ANK 2"
FT   REPEAT          444..473
FT                   /note="ANK 3"
FT   REPEAT          477..506
FT                   /note="ANK 4"
FT   REPEAT          510..539
FT                   /note="ANK 5"
FT   REPEAT          543..572
FT                   /note="ANK 6"
FT   REPEAT          576..605
FT                   /note="ANK 7"
FT   REPEAT          609..638
FT                   /note="ANK 8"
FT   DOMAIN          681..955
FT                   /note="Roc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00758"
FT   REPEAT          875..904
FT                   /note="ANK 9"
FT   REPEAT          1162..1196
FT                   /note="ANK 10"
FT   DOMAIN          1312..1396
FT                   /note="Death"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00064"
FT   REGION          267..334
FT                   /note="Calmodulin-binding"
FT   REGION          292..301
FT                   /note="Autoinhibitory domain"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        139
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         19..27
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         42
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         94..96
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         100
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         161
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         289
FT                   /note="Phosphoserine; by RPS6KA1 and RPS6KA3"
FT                   /evidence="ECO:0000269|PubMed:16213824"
FT   MOD_RES         308
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11579085,
FT                   ECO:0000269|PubMed:15729359, ECO:0000269|PubMed:17056602"
FT   MOD_RES         319
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         333
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         734
FT                   /note="Phosphoserine; by MAPK1"
FT                   /evidence="ECO:0000269|PubMed:15616583"
FT   MOD_RES         1115
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80YE7"
FT   VAR_SEQ         1..446
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042053"
FT   VAR_SEQ         742..783
FT                   /note="VSVSINNLYPGCENVSVRSRSMMFEPGLTKGMLEVFVAPTHH -> GRNLHA
FT                   GPVSPAGVGFRTLSFQGLGGKGVVFGSLGLYWTLWP (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042054"
FT   VAR_SEQ         784..1430
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042055"
FT   VAR_SEQ         805..870
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_054478"
FT   VAR_SEQ         1430
FT                   /note="R -> RRNSHVWNPTV (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_042056"
FT   VARIANT         416
FT                   /note="V -> I (in dbSNP:rs12343465)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_033235"
FT   VARIANT         461
FT                   /note="A -> S"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040420"
FT   VARIANT         519
FT                   /note="S -> A"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040421"
FT   VARIANT         540
FT                   /note="C -> Y (in dbSNP:rs56327474)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040422"
FT   VARIANT         591
FT                   /note="P -> L (in dbSNP:rs36214022)"
FT                   /evidence="ECO:0000269|Ref.5"
FT                   /id="VAR_060693"
FT   VARIANT         622
FT                   /note="I -> M (in dbSNP:rs36215047)"
FT                   /evidence="ECO:0000269|Ref.5"
FT                   /id="VAR_060694"
FT   VARIANT         941
FT                   /note="M -> T"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040423"
FT   VARIANT         977
FT                   /note="R -> W"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040424"
FT   VARIANT         978
FT                   /note="K -> N"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040425"
FT   VARIANT         993
FT                   /note="Y -> C"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040426"
FT   VARIANT         994
FT                   /note="D -> E"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040427"
FT   VARIANT         1005
FT                   /note="E -> Q"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040428"
FT   VARIANT         1007
FT                   /note="D -> Y"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040429"
FT   VARIANT         1008
FT                   /note="L -> P"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040430"
FT   VARIANT         1010
FT                   /note="R -> C (in dbSNP:rs371784492)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040431"
FT   VARIANT         1018
FT                   /note="T -> A"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040432"
FT   VARIANT         1272
FT                   /note="M -> I (in dbSNP:rs56169226)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040433"
FT   VARIANT         1346
FT                   /note="S -> N (in dbSNP:rs1056719)"
FT                   /evidence="ECO:0000269|PubMed:15164053,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:17974005,
FT                   ECO:0000269|PubMed:7828849, ECO:0000269|Ref.5"
FT                   /id="VAR_040434"
FT   VARIANT         1405
FT                   /note="G -> V (in dbSNP:rs36220450)"
FT                   /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.5"
FT                   /id="VAR_040435"
FT   MUTAGEN         42
FT                   /note="K->A: Loss of activity, apoptotic function and of
FT                   autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:11579085,
FT                   ECO:0000269|PubMed:7828849"
FT   MUTAGEN         289
FT                   /note="S->A: Loss of phosphorylation and significant
FT                   increase in proapoptotic activity."
FT   MUTAGEN         289
FT                   /note="S->E: Reduction in proapoptotic activity."
FT   MUTAGEN         308
FT                   /note="S->A: Elevated Ca(2+)-calmodulin binding and
FT                   Ca(2+)-calmodulin-independent kinase activity. Increases
FT                   apoptotic activity."
FT                   /evidence="ECO:0000269|PubMed:11579085"
FT   MUTAGEN         308
FT                   /note="S->D: Reduced Ca(2+)-calmodulin binding and
FT                   Ca(2+)-calmodulin-independent kinase activity. Decreases
FT                   apoptotic activity."
FT                   /evidence="ECO:0000269|PubMed:11579085"
FT   MUTAGEN         313
FT                   /note="S->A: Minimal effect on activity."
FT                   /evidence="ECO:0000269|PubMed:11579085"
FT   CONFLICT        490
FT                   /note="Y -> H (in Ref. 3; BAC87163)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1217
FT                   /note="S -> G (in Ref. 4; CAH18690)"
FT                   /evidence="ECO:0000305"
FT   HELIX           9..11
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   STRAND          13..21
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   STRAND          23..32
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   TURN            33..35
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   STRAND          38..46
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   STRAND          48..51
FT                   /evidence="ECO:0007829|PDB:2W4J"
FT   STRAND          53..56
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   HELIX           58..70
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   STRAND          79..84
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   STRAND          86..94
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   HELIX           101..107
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   STRAND          108..110
FT                   /evidence="ECO:0007829|PDB:3ZXT"
FT   HELIX           113..132
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   STRAND          134..136
FT                   /evidence="ECO:0007829|PDB:1JKT"
FT   HELIX           142..144
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   STRAND          145..148
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   STRAND          150..154
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   STRAND          157..159
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   HELIX           162..164
FT                   /evidence="ECO:0007829|PDB:4UV0"
FT   STRAND          169..171
FT                   /evidence="ECO:0007829|PDB:2W4J"
FT   HELIX           181..183
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   HELIX           186..189
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   HELIX           197..212
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   HELIX           222..230
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   HELIX           238..241
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   STRAND          242..244
FT                   /evidence="ECO:0007829|PDB:1P4F"
FT   HELIX           246..255
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   TURN            260..262
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   HELIX           266..271
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   TURN            273..275
FT                   /evidence="ECO:0007829|PDB:4PF4"
FT   HELIX           280..288
FT                   /evidence="ECO:0007829|PDB:4B4L"
FT   HELIX           293..302
FT                   /evidence="ECO:0007829|PDB:4B4L"
FT   HELIX           304..318
FT                   /evidence="ECO:0007829|PDB:1YR5"
FT   TURN            1338..1340
FT                   /evidence="ECO:0007829|PDB:6GY5"
SQ   SEQUENCE   1430 AA;  160046 MW;  E2C4246E7C78A6D2 CRC64;
     MTVFRQENVD DYYDTGEELG SGQFAVVKKC REKSTGLQYA AKFIKKRRTK SSRRGVSRED
     IEREVSILKE IQHPNVITLH EVYENKTDVI LILELVAGGE LFDFLAEKES LTEEEATEFL
     KQILNGVYYL HSLQIAHFDL KPENIMLLDR NVPKPRIKII DFGLAHKIDF GNEFKNIFGT
     PEFVAPEIVN YEPLGLEADM WSIGVITYIL LSGASPFLGD TKQETLANVS AVNYEFEDEY
     FSNTSALAKD FIRRLLVKDP KKRMTIQDSL QHPWIKPKDT QQALSRKASA VNMEKFKKFA
     ARKKWKQSVR LISLCQRLSR SFLSRSNMSV ARSDDTLDEE DSFVMKAIIH AINDDNVPGL
     QHLLGSLSNY DVNQPNKHGT PPLLIAAGCG NIQILQLLIK RGSRIDVQDK GGSNAVYWAA
     RHGHVDTLKF LSENKCPLDV KDKSGEMALH VAARYGHADV AQLLCSFGSN PNIQDKEEET
     PLHCAAWHGY YSVAKALCEA GCNVNIKNRE GETPLLTASA RGYHDIVECL AEHGADLNAC
     DKDGHIALHL AVRRCQMEVI KTLLSQGCFV DYQDRHGNTP LHVACKDGNM PIVVALCEAN
     CNLDISNKYG RTPLHLAANN GILDVVRYLC LMGASVEALT TDGKTAEDLA RSEQHEHVAG
     LLARLRKDTH RGLFIQQLRP TQNLQPRIKL KLFGHSGSGK TTLVESLKCG LLRSFFRRRR
     PRLSSTNSSR FPPSPLASKP TVSVSINNLY PGCENVSVRS RSMMFEPGLT KGMLEVFVAP
     THHPHCSADD QSTKAIDIQN AYLNGVGDFS VWEFSGNPVY FCCYDYFAAN DPTSIHVVVF
     SLEEPYEIQL NQVIFWLSFL KSLVPVEEPI AFGGKLKNPL QVVLVATHAD IMNVPRPAGG
     EFGYDKDTSL LKEIRNRFGN DLHISNKLFV LDAGASGSKD MKVLRNHLQE IRSQIVSVCP
     PMTHLCEKII STLPSWRKLN GPNQLMSLQQ FVYDVQDQLN PLASEEDLRR IAQQLHSTGE
     INIMQSETVQ DVLLLDPRWL CTNVLGKLLS VETPRALHHY RGRYTVEDIQ RLVPDSDVEE
     LLQILDAMDI CARDLSSGTM VDVPALIKTD NLHRSWADEE DEVMVYGGVR IVPVEHLTPF
     PCGIFHKVQV NLCRWIHQQS TEGDADIRLW VNGCKLANRG AELLVLLVNH GQGIEVQVRG
     LETEKIKCCL LLDSVCSTIE NVMATTLPGL LTVKHYLSPQ QLREHHEPVM IYQPRDFFRA
     QTLKETSLTN TMGGYKESFS SIMCFGCHDV YSQASLGMDI HASDLNLLTR RKLSRLLDPP
     DPLGKDWCLL AMNLGLPDLV AKYNTSNGAP KDFLPSPLHA LLREWTTYPE STVGTLMSKL
     RELGRRDAAD FLLKASSVFK INLDGNGQEA YASSCNSGTS YNSISSVVSR
//
